Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster

Lloren, Khristine Kaith S.; Jawalagatti, Vijayakumar; Hewawaduge, Chamith; Sivasankar, Chandran; Park, Jiyoung; Lee, John Hwa

doi:10.1016/j.micinf.2023.105101

Cited by 4 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27] In addition, Salmonella was engineered to deliver a self-replicating oral coronavirus disease-2019 (COVID-19) RNA vaccine. [28] Therefore, VNP shows high promise as a carrier and shows some degree of clinical safety.…”

Section: Discussionmentioning

confidence: 99%

Flagella of Tumor‐Targeting Bacteria Trigger Local Hemorrhage to Reprogram Tumor‐Associated Macrophages for Improved Antitumor Therapy

Xiong

Chen

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Tumor‐associated macrophages (TAMs) exhibit an immunosuppressive M2 phenotype and lead to failure of antitumor therapy. Infiltrated erythrocytes during hemorrhage are recognized as a promising strategy for polarizing TAMs. However, novel materials that precisely induce tumor hemorrhage without affecting normal coagulation still face challenges. Here, tumor‐targeting bacteria (flhDC VNP) are genetically constructed to realize precise tumor hemorrhage. FlhDC VNP colonizes the tumor and overexpresses flagella during proliferation. The flagella promote the expression of tumor necrosis factor α, which induces local tumor hemorrhage. Infiltrated erythrocytes during the hemorrhage temporarily polarize macrophages to the M1 subtype. In the presence of artesunate, this short‐lived polarization is transformed into a sustained polarization because artesunate and heme form a complex that continuously produces reactive oxygen species. Therefore, the flagella of active tumor‐targeting bacteria may open up new strategies for reprogramming TAMs and improving antitumor therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Flagella of Tumor‐Targeting Bacteria Trigger Local Hemorrhage to Reprogram Tumor‐Associated Macrophages for Improved Antitumor Therapy

Xiong

Chen

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Various modifications are feasible by introducing mRNA into cells such as immune cells, blood cells, and others. − Recently, a bacteria-mediated vehicle for oral mRNA vaccine delivery has been also developed. This multiple-target vaccine successfully explored engineered Salmonella-based vector to deliver mRNA vaccine against Delta and Omicron variants of COVID-19. , …”

Section: Outlook and Perspectivesmentioning

confidence: 99%

“…This multiple-target vaccine successfully explored engineered Salmonella-based vector to deliver mRNA vaccine against Delta and Omicron variants of COVID-19. 86,87 • Targeting mRNA therapeutics to certain tissues and engineering of delivery systems with tissue-specif ic af f inity. Fulfilling the potential of mRNA therapeutics requires proper targeting.…”

Section: ■ Outlook and Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?

Liu

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

With the rapid success in the development of mRNA vaccines against COVID-19 and with a number of mRNAbased drugs ahead in the pipelines, mRNA has catapulted to the forefront of drug research, demonstrating its substantial effectiveness against a broad range of diseases. As the recent global pandemic gradually fades, we cannot stop thinking about what the world has gained: the realization and validation of the power of mRNA in modern medicine. A significant amount of research has now been concentrated on developing mRNA drugs and vaccine platforms against infectious and immune diseases, cancer, and other debilitating diseases and has demonstrated encouraging results. Here, based on the CAS Content Collection, we provide a landscape view of the current state, outline trends in the research and development of mRNA therapeutics and vaccines, and highlight some notable patents focusing on mRNA therapeutics, vaccines, and delivery systems. Analysis of diseases disclosed in patents also reveals highly investigated diseases for treatments with these medicines. Finally, we provide information about mRNA therapeutics and vaccines in clinical trials. We hope this Review will be useful for understanding the current knowledge in the field of mRNA medicines and will assist in efforts to solve its remaining challenges and revolutionize the treatment of human diseases.

show abstract

“…Upon experimental intra-nasal infection with SARS-CoV-2, Syrian hamsters show robust viral replication and moderate to severe clinical signs very early after infection, including weight loss and pulmonary pathology similar to that of humans [ 13 ]. Studies investigating the performance of oral and nasal vaccines directed against SARS-CoV-2 in the Syrian hamster have shown promising immunogenicity profiles [ 14 ] and protection from lung pathology, pulmonary viral load and clinical disease following viral challenge [ 14 , 15 , 16 , 17 , 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Hamsters

Wood,

Hughes,

Trussell

et al. 2024

Vaccines

View full text Add to dashboard Cite

Oral vaccines, unlike injected, induce intestinal secretory immunoglobulin A (sIgA) mimicking our natural defense against gut pathogens. We previously observed sIgA responses after administering the Clostridioides difficile colonisation factor CD0873 orally in enteric capsules to hamsters. Enteric-coated capsules are designed to resist dissolution in the stomach and disintegrate only at the higher pH of the small intestine. However, the variable responses between animals led us to speculate suboptimal transit of antigens to the small intestine. The rate of gastric emptying is a controlling factor in the passage of oral drugs for subsequent availability in the small intestine for absorption. Whilst in humans, food delays gastric emptying, in rats, capsules can empty quicker from fed stomachs than from fasted. To test in hamsters if fasting improves the delivery of antigens to the small intestine, as inferred from the immune responses generated, 24 animals were dosed intragastrically with enteric capsules containing recombinant CD0873. Twelve hamsters were fasted for 12 h prior to each dose and the other 12 fed. Significantly higher sIgA titres, with significantly greater bacterial-adherence-blocking activity, were detected in small intestinal lavages in the fasted group. We conclude that fasting in hamsters improves intestinal delivery leading to more robust responses.

show abstract

Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster

Cited by 4 publications

References 50 publications

Flagella of Tumor‐Targeting Bacteria Trigger Local Hemorrhage to Reprogram Tumor‐Associated Macrophages for Improved Antitumor Therapy

Flagella of Tumor‐Targeting Bacteria Trigger Local Hemorrhage to Reprogram Tumor‐Associated Macrophages for Improved Antitumor Therapy

Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?

Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Hamsters

Contact Info

Product

Resources

About